L’Abbé plot for the incidence of adverse events in the MSCs therapy group and control group.
deaths, gastrointestinal tract bleeding
MALIGNANCIES
Decreased total protein and globulin levels and increased albumin and hemoglobin levels after DMARDs plus UC-MSCs administration in comparison with the control group had shown in the study of Wang et al.; the function of the liver could be estimated based on this elevation in levels of albumin and hemoglobin and based on the decreased incidence of gastrointestinal tract bleeding. Álvaro-Gracia et al. not reported abnormal laboratory values nor relevant vital sign abnormalities, malignancies, or deaths. The study of Yang et al. was not found significant abnormalities in a routine blood test, liver, and kidney function analysis, urine analysis, or electrocardiography.